# US 9,040,546 B2 · Method of treating functional somatic syndromes with combination of famciclovir and celecoxib

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,040,546 B2
- Document ID: US9040546B2
- Status: Granted
- Kind: B2
- Application number: 14/251,345
- Filed: 2014-04-11
- Published: 2014-08-07
- Granted: 2015-05-26
- Earliest claimed: 2012-02-06
- Assignees: Innovative Med Concepts, LLC
- Applicants: Innovative Med Concepts, LLC
- Inventors: William L. Pridgen
- Web page: https://patentgrep.com/patent/US9040546B2

## CPC

- A61K 31/196: the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
- A61K 31/415: 1,2-Diazoles
- A61K 31/427: not condensed and containing further heterocyclic rings
- A61K 31/52: Purines, e.g. adenine
- A61K 31/522: having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A61K 31/5415: ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
- A61K 31/5575: having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
- A61K 31/635: having a heterocyclic ring, e.g. sulfadiazine
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 13/10: of the bladder
- A61P 13/12: of the kidneys
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/02: Immunomodulators
- A61P 39/00: General protective or antinoxious agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to methods of treating fibromyalgia by administering a therapeutically-effective combination-dosage of famciclovir and celecoxib. The invention is also related to methods of treating functional somatic syndromes by administering a therapeutically-effective combination-dosage of famciclovir and celecoxib.

## Claims

### Claim 1

A method to treat a subject susceptible to or afflicted with one or more functional somatic syndrome conditions, the method comprising administering to the subject a co-acting combination of famciclovir and celecoxib therapeutically-effective to treat at least one functional somatic syndrome condition selected from fibromyalgia, chronic fatigue syndrome and irritable bowel syndrome wherein each of famciclovir and celecoxib is administered in a dosage amount co-acting in combination to provide therapeutically-effective treatment of at least one functional somatic syndrome condition.

### Claim 2 (depends on 1)

The method of claim 1, wherein the treatment-subject has fibromyalgia condition and a gastrointestinal disorder arising from HSV-1 gastrointestinal-tract infection.

### Claim 3 (depends on 1)

The method of claim 1, wherein the therapeutically-effective treatment provides an improved adverse event profile.

### Claim 4 (depends on 1)

The method of claim 1, wherein one or more functional somatic syndrome conditions are fibromyalgia and chronic fatigue syndrome, coexistent in the subject.

### Claim 5 (depends on 1)

The method of claim 1, wherein one or more functional somatic syndrome conditions are fibromyalgia and irritable bowel syndrome, coexistent in the subject.